Henderson, Nev.-based Corstasis Therapeutics has entered a strategic collaboration with US Heart and Vascular to improve outpatient management of heart failure using Enbumyst, a nasal spray formulation of bumetanide.
The FDA recently approved Enbumyst for treatment of edema in adults with heart failure and other conditions.
The partnership aims to codevelop value-based care pathways for earlier intervention in fluid overload associated with congestive heart failure, liver disease and chronic kidney disease. Plans include clinical workflow protocols, provider training and data collection to support payer engagement, according to a Sept. 25 system news release.
